October 2025

Evkeeza® (evinacumab-dgnb) Injection

CODING & BILLING GUIDE

for EVKEEZA® (evinacumab-dgnb)

A concise reference of diagnostic, administration, product, and revenue codes that can help payers recognize, process, and pay claims for EVKEEZA.

INDICATION

EVKEEZA is an angiopoietin-like 3 (ANGPTL3) inhibitor indicated as an adjunct to diet and exercise and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies to reduce LDL-C in adults and pediatric patients, aged 1 year and older, with homozygous familial hypercholesterolemia (HoFH).

IMPORTANT SAFETY INFORMATION

Contraindication

EVKEEZA is contraindicated in patients with a history of serious hypersensitivity reaction to evinacumab-dgnb or to any of the excipients in EVKEEZA. Serious hypersensitivity reactions, including anaphylaxis, have occurred.

Please see Important Safety Information throughout and accompanying full Prescribing Information.

Evkeeza® (evinacumab-dgnb) Injection

A resource for coding, billing, and reimbursement for EVKEEZA

This guide provides **coding and billing information** to assist with understanding the **reimbursement for EVKEEZA administered in the office or hospital outpatient setting.**

This resource includes:

- **Diagnosis coding**: *International Classification of Diseases, 10th Revision, Clinical Modification* (ICD-10-CM) codes
- **Administration coding**: Current Procedural Terminology (CPT®) codes*
- **Product coding**: Healthcare Common Procedure Coding System (HCPCS) Level II codes
- **Revenue codes**
- **Product information**

The coding information discussed in this guide is provided for informational purposes only, is subject to change and interpretation, and should not be construed as legal advice. The codes listed herein may not apply to all patients or to all health plans. Conversely, additional codes not listed in this guide may apply to some patients. Providers should follow payer-specific coding requirements and exercise independent clinical judgment when selecting codes and submitting claims to accurately reflect the services and products furnished to a specific patient. Providers must determine whether it is appropriate to submit any particular claim for reimbursement. Information provided in this guide is effective as of **[October 2025]**.

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions

Serious Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, have occurred with EVKEEZA. If signs or symptoms of serious hypersensitivity reactions occur, discontinue EVKEEZA infusion, treat according to the standard-of-care, and monitor until signs and symptoms resolve.

Please see Important Safety Information throughout and accompanying full Prescribing Information.

The following 2 most common billing claim forms from the Centers for Medicare & Medicaid Services (CMS) are available at **https://www.cms.gov/medicare/forms-notices/cms-forms-list:**

- **CMS-1500** (print) or **837P** (electronic) for physician office reimbursement
- **UB-04** (also known as CMS-1450) (print) or **837I** (electronic) for hospital outpatient reimbursement

Sample annotated versions of these forms are available for your reference at EVKEEZAhcp.com

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions (cont'd)

Embryo-Fetal Toxicity: EVKEEZA may cause fetal harm when administered to pregnant patients. Advise patients who may become pregnant of the risk to a fetus. Consider obtaining a pregnancy test prior to initiating treatment with EVKEEZA. Advise patients who may become pregnant to use effective contraception during treatment and for at least 5 months following the last dosage.

Please see Important Safety Information throughout and accompanying full Prescribing Information.

Diagnosis coding: ICD-10-CM codes

The diagnosis code selected should reflect the highest level of specificity available as documented in the patient's medical record.

The following ICD-10-CM diagnosis code is the most specific code available for homozygous familial hypercholesterolemia (HoFH).[1]

ICD-10-CM code	Description
E78.010	Homozygous familial hypercholesterolemia (HoFH)

Administration coding: CPT codes for EVKEEZA

CPT codes are assigned by physicians and by hospitals for outpatient services involving the administration of medications, including EVKEEZA.

EVKEEZA is an angiopoietin-like 3 inhibitor indicated as an adjunct to diet and exercise and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies to reduce LDL-C in adults and pediatric patients, aged 1 year and older, with HoFH. EVKEEZA is delivered by intravenous (IV) infusion.

The following CPT codes apply to the administration of EVKEEZA.

CPT code	Description
IV administration—therapeutic codes	
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
IV administration—chemotherapy codes	
96413	Chemotherapy administration, intravenous infusion technique, up to 1 hour, single or initial substance/drug

IMPORTANT SAFETY INFORMATION (cont'd)

Adverse Reactions

Adults and Pediatric Patients (12 to 17 years): Common adverse reactions (≥5%) were nasopharyngitis (16%), influenza-like illness (7%), dizziness (6%), rhinorrhea (5%), and nausea (5%).

Please see Important Safety Information throughout and accompanying full Prescribing Information.

Evkeeza® (evinacumab-dgnb) Injection

Product coding: HCPCS Level II codes for EVKEEZA

Permanent J-code

HCPCS Level II codes help identify medications, including EVKEEZA, and are assigned in addition to the CPT code.

HCPCS J-code	Description	Billing units
J1305	Injection, evinacumab-dgnb, 5 mg	5 mg=1 billing unit

Medicare requires the use of the JW modifier for reporting discarded amounts of drug. **Effective July 1, 2023,** the JZ modifier is required for reporting there was no discarded drug.

Revenue coding for hospital administration

Use of revenue codes allow hospitals to bill for services provided.

Revenue code	Description
Administration	
0510	Clinic
0500	Outpatient services
Drug	
0636	Drugs requiring detailed coding
0250	Drugs and biologicals
0260	IV therapy

Product information for EVKEEZA

Drug name/strength	10-digit NDC#	11-digit NDC#*
EVKEEZA 345 mg/2.3 mL (150 mg/mL)	61755-013-01	61755-**0**013-01
EVKEEZA 1200 mg/8 mL (150 mg/mL)	61755-010-01	61755-**0**010-01

*The product's NDC has been 'zero-filled' to ensure creation of an 11-digit code that meets general billing standards. The zero-fill location is indicated in bold.

IMPORTANT SAFETY INFORMATION (cont'd)

Adverse Reactions (cont'd)

Pediatric Patients (5 to 11 years): The safety profile was consistent with that observed in adults and pediatric patients aged 12 and older, with the additional adverse reaction of fatigue in 3 (15%) patients.

Please see Important Safety Information throughout and accompanying full Prescribing Information.

If you have questions about coding and billing for EVKEEZA, please call us at

1-877-EVKEEZA (1-877-385-3392) **Option 1**,
Monday–Friday, 9 AM–9 PM Eastern time

For returns of product damaged in shipment and unused drugs appropriately discarded, please call **1-877-EVKEEZA** (1-877-385-3392) **Option 4**, Monday–Friday, 9 AM–9 PM Eastern time

IMPORTANT SAFETY INFORMATION (cont'd)

Use in Specific Populations

Pregnancy: EVKEEZA may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. If a patient becomes pregnant while receiving EVKEEZA, healthcare providers should report EVKEEZA exposure by calling 1-833-385-3392.

Lactation: There are no data on the presence of evinacumab-dgnb in human milk or animal milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EVKEEZA and any potential adverse effects on the breastfed infant from EVKEEZA or from the underlying maternal condition.

Females and Males of Reproductive Potential: Consider pregnancy testing in patients who may become pregnant prior to starting treatment with EVKEEZA. EVKEEZA may cause fetal harm when administered to a pregnant woman. Females of reproductive potential should use effective contraception during treatment with EVKEEZA and for at least 5 months following the last dosage of EVKEEZA.

Pediatrics: The safety profile of EVKEEZA in pediatric patients aged 1 to 11 years was similar to the safety profile in adults and pediatric patients aged 12 years and older, with the additional adverse reaction of fatigue in patients aged 5 to 11 years. The safety and effectiveness of EVKEEZA have not been established in pediatric patients younger than 1 year of age.

Please see accompanying full Prescribing Information.

Reference: 1. Centers for Disease Control and Prevention. National Center for Health Statistics – ICD-10-CM. Accessed October 28, 2025. https://icd10cmtool.cdc.gov/?fy=FY2026&query=HOFH

REGENERON®

10/2025 US.EVK.25.06.0014

Evkeeza®
(evinacumab-dgnb)
Injection